Table 1.
Patient characteristics
| Characteristic | Vemurafenib Monotherapy (n=172) |
|---|---|
| Median age (range), years | 60 (18–90) |
| Age group, years | |
| 18–64 | 112 (65) |
| 65–84 | 57 (33) |
| ≥85 | 3 (2) |
| Sex, No. (%) | |
| Male | 82 (48) |
| Female | 90 (52) |
| Primary tumor, No. (%) | |
| Non-small cell lung cancer | 63 (37) |
| Histiocytosis | 27 (16) |
| Glioma | 24 (14) |
| Anaplastic thyroid | 12 (7) |
| Colorectal cancer | 10 (6) |
| Cholangiocarcinoma | 9 (5) |
| Sarcoma | 6 (3) |
| Cancer of unknown primary | 5 (3) |
| Ovarian | 4 (2) |
| Neuroendocrine, NOS | 3 (2) |
| Pancreatic | 3 (2) |
| Othersa | 6 (3) |
| BRAF mutation, No. (%) | |
| V600E | 170 (99) |
| V600, other/unknown | 2 (1) |
| ECOG performance status, No. (%) | (n=155) |
| 0 | 47 (30) |
| 1 | 81 (52) |
| 2 | 27 (17) |
| No. of prior systemic therapies, No. (%) | |
| 0 | 28 (16) |
| 1 | 56 (33) |
| 2 | 43 (25) |
| 3+ | 45 (26) |
| Median (range) | 2 (0–10) |
| Median time since diagnosis (range), months | 12.6 (0.9–232.4) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, Not Otherwise Specified.
a
Others were neuroendocrine, head and neck, cervix, squamous cell, and esophageal cancers.